EP0238259B1
(en)
|
1986-03-12 |
1993-09-29 |
American Cyanamid Company |
Macrolide compounds
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DE69129226T2
(de)
|
1990-01-24 |
1998-07-30 |
Douglas I Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
CA2157766A1
(en)
|
1993-03-29 |
1994-10-13 |
Ambikaipakan Balasubramaniam |
Analogs of peptide yy and uses thereof
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
WO1995033474A1
(fr)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Composition medicinale
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
BR9604880A
(pt)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
DK0944648T3
(da)
|
1996-08-30 |
2007-07-02 |
Novo Nordisk As |
GLP-1 derivater
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
ATE289517T1
(de)
|
1996-11-12 |
2005-03-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
AU1159897A
(en)
|
1996-11-13 |
1998-06-03 |
University Of Cincinnati, The |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
ATE265224T1
(de)
|
1998-02-27 |
2004-05-15 |
Novo Nordisk As |
Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
DE69942306D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
CA2334298C
(en)
|
1998-06-08 |
2008-01-08 |
Schering Corporation |
Neuropeptide y5 receptor antagonists
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
WO2000007617A1
(en)
|
1998-07-31 |
2000-02-17 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
KR20050037004A
(ko)
|
1998-12-07 |
2005-04-20 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Glp-1의 유사체
|
ATE309197T1
(de)
|
1999-02-05 |
2005-11-15 |
Emisphere Tech Inc |
Verfahren zur herstellung alkylierter salicylamide
|
ES2301477T3
(es)
|
1999-02-22 |
2008-07-01 |
Merrion Research I Limited |
Forma de dosificacion oral solida que contiene un potenciador.
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
AU3240900A
(en)
|
1999-02-22 |
2000-09-04 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
CA2372214A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
CN1191273C
(zh)
|
1999-05-17 |
2005-03-02 |
康久化学公司 |
长效促胰岛肽
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
AU2001275231A1
(en)
|
2000-06-02 |
2001-12-11 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
US7271149B2
(en)
|
2000-12-07 |
2007-09-18 |
Eli Lilly And Company |
GLP-1 fusion proteins
|
WO2002048192A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
BR0116206A
(pt)
|
2000-12-14 |
2003-12-23 |
Amylin Pharmaceuticals Inc |
Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
DE60230818D1
(de)
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
AU2002352974A1
(en)
|
2001-11-29 |
2003-06-10 |
Emisphere Technologies, Inc. |
Formulations for oral administration of cromolyn sodium
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
JP2005526020A
(ja)
|
2002-02-01 |
2005-09-02 |
ファイザー・プロダクツ・インク |
アジスロマイシンの乾式造粒配合物
|
MXPA04008068A
(es)
*
|
2002-02-20 |
2004-11-26 |
Lilly Co Eli |
Metodo para administrar moleculas de glp-1.
|
JP5685355B2
(ja)
|
2002-07-04 |
2015-03-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1および糖尿病の処置方法
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
WO2004066966A2
(en)
|
2003-01-17 |
2004-08-12 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Peptide yy analogs
|
WO2004067548A2
(en)
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
CN1832959A
(zh)
|
2003-03-19 |
2006-09-13 |
伊莱利利公司 |
聚乙二醇连接的glp-1化合物
|
AU2004241242A1
(en)
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
JP5032844B2
(ja)
|
2003-07-11 |
2012-09-26 |
ノバルティス アーゲー |
微粉末形態の送達物質を含む経口投与用医薬組成物
|
WO2005014049A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk A/S |
Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
|
CA2539253A1
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
AU2004290862B2
(en)
|
2003-11-20 |
2010-06-03 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
CA2550050A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
EP2335716A3
(en)
|
2004-02-11 |
2011-10-19 |
Amylin Pharmaceuticals Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
EP2417980A1
(en)
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
CN101361967A
(zh)
|
2004-03-17 |
2009-02-11 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y2/y4选择性受体激动剂
|
EP1729792B1
(en)
|
2004-03-17 |
2010-12-08 |
7TM Pharma A/S |
Y4 selective receptor agonist for therapeutic interventions
|
WO2005089789A2
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
US20080261871A1
(en)
|
2004-03-17 |
2008-10-23 |
7Tm Pharma A/S |
Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
WO2005107773A2
(en)
|
2004-05-06 |
2005-11-17 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
CN102040535B
(zh)
|
2004-05-06 |
2012-10-17 |
爱密斯菲尔科技公司 |
N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
|
JP5254610B2
(ja)
*
|
2004-05-14 |
2013-08-07 |
エミスフェアー・テクノロジーズ・インク |
活性薬剤を送達するための化合物および組成物
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US20070021346A1
(en)
|
2005-05-26 |
2007-01-25 |
Ewing William R |
N-terminally modified GLP-1 receptor modulators
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
RU2006144821A
(ru)
|
2004-07-08 |
2008-08-20 |
Ново Нордиск А/С (DK) |
Пролонгирующие метки полипептидов, содержащие тетразольную группировку
|
JP5749879B2
(ja)
|
2004-07-12 |
2015-07-15 |
エミスフェアー・テクノロジーズ・インク |
ペプチドyyおよびペプチドyyアゴニストの送達用組成物
|
WO2006020207A2
(en)
|
2004-07-19 |
2006-02-23 |
University Of Cincinnati |
Compounds for control of appetite
|
JP2008509933A
(ja)
|
2004-08-13 |
2008-04-03 |
エミスフェアー・テクノロジーズ・インク |
送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
WO2006060855A1
(en)
|
2004-12-09 |
2006-06-15 |
Radial Corporation Limited |
Material handling for radial timber sawing
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
US20080153779A1
(en)
|
2005-02-01 |
2008-06-26 |
Jun Liao |
Gastric Retention and Controlled Release Delivery System
|
EP1846446B1
(en)
|
2005-02-02 |
2013-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
JP2008531059A
(ja)
|
2005-03-04 |
2008-08-14 |
バイオレクシス ファーマシューティカル コーポレーション |
改変トランスフェリン融合タンパク質
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
TWI372629B
(en)
*
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
CN101128214A
(zh)
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
长效glp-1化合物
|
WO2006097536A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
CA2603105A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
JP2009500453A
(ja)
|
2005-07-11 |
2009-01-08 |
ナステック ファーマスーティカル カンパニー インク. |
向上されたpyyの粘膜送達用製剤
|
WO2007011958A2
(en)
|
2005-07-15 |
2007-01-25 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
EP1907010A2
(en)
|
2005-07-18 |
2008-04-09 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
CN105056211A
(zh)
|
2005-08-19 |
2015-11-18 |
安米林药品有限责任公司 |
治疗糖尿病和降低体重的毒蜥外泌肽
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
US8022035B2
(en)
|
2005-09-21 |
2011-09-20 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
WO2007038943A1
(en)
|
2005-09-21 |
2007-04-12 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
EP1951207A2
(en)
|
2005-11-17 |
2008-08-06 |
Novartis AG |
Pharmaceutical composition
|
EP1962959B1
(en)
|
2005-12-07 |
2012-03-14 |
F. Hoffmann-La Roche AG |
Neuropeptide-2 receptor-agonists
|
JP2009520693A
(ja)
|
2005-12-08 |
2009-05-28 |
エムディーアールエヌエー,インコーポレイテッド |
安定化されたエキセンディン製剤の粘膜送達
|
EP1963343A1
(en)
|
2005-12-14 |
2008-09-03 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
MX2008012678A
(es)
|
2006-04-07 |
2008-12-17 |
Merrion Res Iii Ltd |
Forma de dosis oral solida que contiene un mejorador.
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
US8933021B2
(en)
|
2006-05-09 |
2015-01-13 |
Novo Nordisk A/S |
Insulin derivative
|
US20070292512A1
(en)
|
2006-06-09 |
2007-12-20 |
Merrion Research Ii Limited |
Solid Oral Dosage Form Containing an Enhancer
|
US9364502B2
(en)
|
2006-06-28 |
2016-06-14 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
CA2662080C
(en)
|
2006-09-07 |
2012-07-17 |
F. Hoffmann-La Roche Ag |
A process for the manufacture of snac (salcaprozate sodium)
|
PE20080840A1
(es)
|
2006-09-13 |
2008-08-27 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
WO2008039351A2
(en)
|
2006-09-22 |
2008-04-03 |
Novartis Ag |
Method of manufacturing tablets containing pharmacologically active agents
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
EP2101822A2
(en)
|
2007-01-18 |
2009-09-23 |
Novo Nordisk A/S |
Use of peptides in combination with surgical intervention for the treatment of obesity
|
US20100016237A1
(en)
|
2007-01-18 |
2010-01-21 |
Novo Nordisk A/S |
Novel Peptides for Use in the Treatment of Obesity
|
JP5249246B2
(ja)
|
2007-03-02 |
2013-07-31 |
ノバルティス アーゲー |
カルシトニンの経口投与
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
EP2514406A1
(en)
|
2007-06-01 |
2012-10-24 |
Novo Nordisk A/S |
Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
|
JP2010530962A
(ja)
|
2007-06-12 |
2010-09-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
血漿においてタンパク質を検出する方法
|
EP2322620A3
(en)
|
2007-07-09 |
2011-08-31 |
Imperial Innovations Ltd. |
Analogs of human pancreatic polypeptide and their effects on feeding behaviour
|
CA2697504A1
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of California |
Salicylanilide modified peptides for use as oral therapeutics
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
US20100204113A1
(en)
|
2007-09-11 |
2010-08-12 |
Dorian Bevec |
Use of stresscopin-related peptide as a therapeutic agent
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
BRPI0818004B8
(pt)
|
2007-10-16 |
2021-05-25 |
Biocon Ltd |
composição farmacêutica sólida administrável por via oral e o processo da mesma.
|
WO2009059188A1
(en)
|
2007-11-02 |
2009-05-07 |
Emisphere Technologies, Inc. |
Method of treating vitamin b12 deficiency
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
CA2723855A1
(en)
|
2008-05-16 |
2009-11-19 |
Novo Nordisk A/S |
Long-acting y2 and/or y4 receptor agonists
|
EP2331072B8
(en)
|
2008-08-18 |
2020-08-26 |
Entera Bio Ltd. |
Methods and compositions for oral administration of proteins
|
CN102149411A
(zh)
|
2008-09-12 |
2011-08-10 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
BRPI0920122B1
(pt)
|
2008-10-15 |
2017-12-19 |
Bayer Intellectual Property Gmbh |
Ditiin-tetracarboximides and their uses for combating phytopathogenic fungi
|
MX2011004427A
(es)
|
2008-11-05 |
2011-05-31 |
Hoffmann La Roche |
Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
NZ619520A
(en)
|
2009-02-13 |
2015-06-26 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
CN102325545A
(zh)
|
2009-02-20 |
2012-01-18 |
益普生制药股份有限公司 |
具有神经肽y受体结合化合物的细胞毒性缀合物
|
ITRM20090347A1
(it)
|
2009-07-03 |
2011-01-04 |
Univ Siena |
Dispositivo di analisi del sistema nervoso centrale attraverso l applicazione di stimoli di diversa natura combinati tra loro e lo studio delle corrispondenti reazioni.
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
EP2477643A1
(en)
|
2009-09-18 |
2012-07-25 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
CN102596228A
(zh)
|
2009-10-13 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
神经肽-2受体(y-2r)激动剂
|
US20130096055A1
(en)
|
2009-11-13 |
2013-04-18 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
JP2013514976A
(ja)
|
2009-12-16 |
2013-05-02 |
ノッド ファーマシューティカルズ, インコーポレイテッド |
経口薬物送達のための組成物および方法
|
CN102791731B
(zh)
|
2009-12-16 |
2016-04-20 |
诺沃—诺迪斯克有限公司 |
Glp-1类似物和衍生物
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
GB2478849A
(en)
|
2010-03-16 |
2011-09-21 |
Chiasma Inc |
Improved pharmecutical compositions and methods of delivery
|
WO2011131646A1
(en)
|
2010-04-20 |
2011-10-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
KR20130093470A
(ko)
|
2010-04-30 |
2013-08-22 |
가부시키가이샤산와카가쿠켄큐쇼 |
생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
EP3326620B1
(en)
|
2010-12-16 |
2020-03-04 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
CA2832811A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
US9382304B2
(en)
|
2011-07-08 |
2016-07-05 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
HUE064694T2
(hu)
|
2012-03-22 |
2024-04-28 |
Novo Nordisk As |
Továbbítószert tartalmazó készítmények és elõállításuk
|
EP4324475A1
(en)
|
2012-03-22 |
2024-02-21 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
WO2013178490A1
(en)
|
2012-05-29 |
2013-12-05 |
Novo Nordisk A/S |
Pancreatic polypeptide compounds and use
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
CA2877056A1
(en)
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
EP3485900A1
(en)
|
2013-05-02 |
2019-05-22 |
Novo Nordisk A/S |
Oral dosing of glp-1 compounds
|
US20160108098A1
(en)
|
2013-05-02 |
2016-04-21 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
US9085637B2
(en)
|
2013-11-15 |
2015-07-21 |
Novo Nordisk A/S |
Selective PYY compounds and uses thereof
|
EP3068795B1
(en)
|
2013-11-15 |
2019-03-06 |
Novo Nordisk A/S |
Hpyy(1-36) having a beta-homoarginine substitution at position 35
|
JP6925969B2
(ja)
|
2015-02-09 |
2021-08-25 |
エンテラ バイオ エルティーディー. |
医薬組成物
|
TWI694082B
(zh)
|
2015-06-12 |
2020-05-21 |
丹麥商諾佛 儂迪克股份有限公司 |
選擇性pyy化合物及其用途
|
CA2997343A1
(en)
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|